Company
OMass Therapeutics
Harnessing proprietary biochemistry, native mass spectrometry and custom chemistry to interrogate not just the target but how it interacts with its native ecosystem, separate from the confounding complexity of the cell
Also known as OMass
- Business model
- B2B
Claim, correct or request removal
Record updated 23 October 2026
About
At OMass Therapeutics, we are identifying new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry. We distil biology to its essential elements – physical interactions within a native ecosystem – to deliver cell-system fidelity and cell-free precision.
Funding snapshot
- Latest round
- Series C, $310M2026-10-16
Funding rounds
- Series C
- $310M2026-10-16, Announced
Products
- Web
- OdyssionTM
- Web
- OMS1620
Loading relationship preview